Professional development Vacancies

SIGNAL Uppsala Monitoring Centre Tocilizumab and pancreatitis (according to the WHO global database VigiBase)

31.03.2021 Updated 26.08.2021 1141 views

Tocilizumab is a humanized monoclonal antibody against interleukin-6 (IL-6) and is indicated for the treatment of rheumatoid arthritis, as well as certain other forms of arthritis. Tocilizumab has also been approved for the treatment of cytokine release syndrome caused by T-cell chimeric antigen receptor therapy and has been used to treat patients with severe COVID-19 infection.

As of November 29, 2020, an analysis by the Uppsala Monitoring Centre identified 5 reports in VigiBase of pancreatitis or acute pancreatitis associated with the use of tocilizumab in the treatment of COVID-19.

In total, there were 189 reports concerning tocilizumab and pancreatitis, regardless of indication. Analysis of 189 reports was considered impractical, so it was limited to 41 reports with more complete information received from Belgium, Croatia, Denmark, France, Germany, Greece, Japan, Spain, and the United Kingdom.

Tocilizumab appears to be a likely cause of pancreatitis, as it was the only suspect medicinal product in 31 of 41 reports. In 25 cases, which occurred in the period from 1 week to 10 months, the time to onset is consistent with other well-recognized drug causes of pancreatitis. Patients were reported to have recovered or to be recovering in 32 of 41 cases, had not recovered in 8 cases, and in the remaining cases the outcome was fatal. In 25 cases, the use of tocilizumab was discontinued, which was accompanied by regression of clinical manifestations. Recovery after withdrawal is consistent with the action of the medicinal product. The literature also contains reports of an association between tocilizumab and pancreatitis.

Analysis of reports from VigiBase

A recent analysis by the Uppsala Monitoring Centre focused on medicinal products used in patients with COVID-19. It is hypothesized that severe COVID-19 infection is associated with a cytokine storm and lung inflammation secondary to a dysregulated host immune response. Since tocilizumab is indicated for the clinical treatment of cytokine release syndrome, it may be useful for reducing the intense inflammatory manifestations associated with severe COVID-19 infection. In 2020, there were many publications describing studies of the use of tocilizumab in patients with COVID-19, and although the results were mixed, a recent publication demonstrated that tocilizumab reduces the likelihood of progression of infection to the composite outcome of mechanical ventilation or death, but did not improve survival. As of 29 November 2020, the Uppsala Monitoring Centre analysis identified 5 individual reports of pancreatitis or acute pancreatitis associated with the use of tocilizumab for the indications "COVID-19" or "Corona virus infection" in the WHO Global database VigiBase. There are 189 reports for this association regardless of indication.

Regarding 189 cases regardless of indication, the IC is 0,6 (observed 189 reports, expected 125), and the IC025 equals 0,4, which indicates a disproportionate association. In 148 reports, tocilizumab is the only suspect medicinal product. The review was limited to those cases in which the most complete information was provided.

The signal review considered 41 reports received from the following countries: France (18 cases), Spain and the United Kingdom (both 5), Japan (4), Germany (3), Croatia and Greece (both 2), Belgium and Denmark (both 1). There was also one more case from Switzerland in a 30-year-old man that met the criteria, but tocilizumab was started after the onset of the reaction, and it was not considered. Most patients were women (26), which is not surprising, since rheumatoid arthritis most often affects women. Age ranged from 5 to 83 years, the mean age was 54,5 years, which was relatively young.

Tocilizumab was the only suspect medicinal product in 31 of 41 cases. Rheumatoid arthritis was reported as the indication for use in 28 reports. In the other 13 cases – Horton's disease, Takayasu's disease, polymyalgia rheumatica, and COVID-19. Doses varied widely depending on the indication and the patient's condition. The most common dose (10 patients) was 162-167 mg per week; 400-720 mg per month was reported in seven patients, and in 5 patients – 560-800 mg over an unknown period.

The time to onset of clinical manifestations of pancreatitis varied widely from 1 day to 8 years, with a median of 5 months. Nine cases were reported within a month, and nine – from 2 to 8 years, while almost half of the cases (18) had onset from 1 to 8 months.

Patients were reported to have recovered or to be recovering in 32 of 41 cases, did not recover in eight cases, and the remaining cases had a fatal outcome. In 25 cases tocilizumab was discontinued. Pancreatitis or acute pancreatitis was the only reaction reported in 28 of 41 reports. Four more cases had additional reactions associated with pancreatitis, such as abdominal pain (4 cases), increased amylase (2) and diarrhea (2). The remaining nine cases had a multitude of other reactions, but no obvious pattern among these reactions, other than some known to be associated with the use of tocilizumab, such as hypertriglyceridemia (3 cases) and abnormal liver function tests (3).

Discussion and conclusions

The analysis by the Uppsala Monitoring Centre identified 189 non-duplicate reports of cases of pancreatitis or acute pancreatitis associated with the use of tocilizumab regardless of indications, with IC 0,6 and IC025 0,4, indicating a disproportionate association. Analysis of 189 reports was considered impractical, so it was limited to those with more complete information.

Tocilizumab appears to be a probable cause of pancreatitis, since it was the only suspected medicinal product in 31 of 41 reports. In the remaining 10 reports there were several suspected medicinal products.

The literature reports several cases of pancreatitis associated with the use of tocilizumab.

In summary, there is a signal of an association between pancreatitis and acute pancreatitis and the use of tocilizumab. There is a significant number of reports in VigiBase, and in those that are well documented, tocilizumab is the only suspected medicinal product in 76% of cases. The time to onset of pancreatitis supports the association, as does recovery after drug withdrawal. There are reports in the literature, and both VigiBase and FAERS show disproportionality in favor of an association.

Перелік лікарських засобів, які містять tocilizumab та дозволені до медичного застосування в Україні (за даними Державного реєстру України станом на 29.03.2021)

Source of information: Signal assessment report “Tocilizumab and Pancreatitis”, Dr. Ian Boyd, Australia, Uppsala Monitoring Centre, March 2021, based on data from the WHO Global Database – VigiBase